Bioeconomy

Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.

Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.

The new Center for Bionic Intelligence Tübingen Stuttgart aims to optimize the interaction between humans and technical systems in a fundamentally new way. Scientists from the Universities of Stuttgart and Tübingen, the Max Planck Institute for Intelligent Systems and the Max Planck Institute for Biological Cybernetics are conducting research on intelligent bionic systems that will aid understanding and treatment of certain diseases of the CNS.

A phase I clinical trial is now starting at Tuebingen University Hospital in the Clinical Collaboration Unit (CCU) Translational Immunology, in collaboration with the Department of Internal Medicine I, which is investigating the therapeutic cancer peptide vaccine Fusion-VAC-XS15 in combination with immune checkpoint blockade by atezolizumab (Tecentriq®).

Tumor vaccines can help the body fight cancer. These vaccines alert the patient's immune system to proteins that are harbouring cancer-typical alterations. Physicians and cancer researchers from Heidelberg and Mannheim have now treated adult patients with advanced midline gliomas, difficult-to-treat brain tumors, with a peptide vaccine for the first time.

The computational design of new proteins for biomedical or other applications involves long computing times on powerful servers. A joint team of researchers from the Max Planck Institute for Biology Tübingen and the University Hospital Tübingen has now developed and tested a new computational method to greatly speed up the necessary energy calculations. Their framework allows for a precise and efficient design of functional proteins.

Can biosurfactants increase microbiological oil degradation in North Sea seawater? An international research team from the universities of Stuttgart und Tübingen, together with the China West Normal University and the University of Georgia, have been exploring this question and the results have revealed the potential for a more effective and environmentally friendly oil spill response.

On Tuesday, July 18, 2023, the Tübingen AI Center held a symposium to celebrate its permanent establishment as a national AI center. Since July 1, 2022, it has received 20 million euros a year in funding from the federal government and the state.

Wearable medical devices, such as soft exoskeletons that provide support for stroke patients or controlled drug delivery patches, have to be made of materials that can adapt intelligently and autonomously to the wearer's movements and to changing environmental conditions. These are the type of autonomously switchable polymer materials that have recently been developed by researchers at the University of Stuttgart and the University of…

Tübingen researchers describe connection between action and feeling of authorship - finding sheds light on delusions of external control in schizophrenia

Effective drugs against viral diseases like COVID-19 are urgently needed now and in the future. The emergence of viral mutants and yet unknown viruses could push vaccines to their limits. The DZIF scientist and bioinformatician Andreas Dräger from the University of Tübingen is working on a computer-based method that can help to accelerate the time-consuming identification and development of antiviral agents. Using a novel analysis technique that…

This month marks the launch of an outstanding project integrating artificial intelligence (AI) and neuromedicine – the Hertie Institute for Artificial Intelligence in Brain Health (Hertie AI). Founded on February 1 at the Medical Faculty of the University of Tübingen, it will be the first institute in Germany to research the prevention and early diagnosis of diseases of the nervous system using artificial intelligence methods.

Tübingen biotechnologist Lars Angenent is being awarded the Leibniz Prize by the German Research Foundation (DFG) in appreciation of his outstanding work in the field of environmental biotechnology, it was announced in Bonn on Thursday. The DFG said: “In view of climate change and the resulting need to develop a sustainable food, chemistry and energy economy, his work is highly relevant.”

Tübingen biotechnologist Lars Angenent is being awarded the Leibniz Prize by the German Research Foundation (DFG) in appreciation of his outstanding work in the field of environmental biotechnology, it was announced in Bonn on Thursday. The DFG said: “In view of climate change and the resulting need to develop a sustainable food, chemistry and energy economy, his work is highly relevant.”

DZNE researchers discover link between the protein medin and Alzheimer's disease. The protein medin is deposited in the blood vessels of the brains of Alzheimer's patients along with the protein amyloid-β. DZNE Researchers have discovered this so-called co-aggregation. They have now published their observation in the renowned journal Nature.

The health of nerve cells is closely linked to the auxiliary cells that surround them, the so-called glial cells. It still remains largely unknown what role glial cells play in age-related diseases.

Heidelberg University scientists are to receive three ERC Synergy Grants – three highly endowed grants of the European Research Council – for pioneering research projects by several teams working in collaboration.

University of Tübingen, a leading member of Cyber Valley, Europe’s largest Artificial Intelligence (AI) research consortium and Boehringer Ingelheim launch an AI and data science fellowship program for top talents from around the world. Three to five fellowships will be awarded per year for up to three years with a target of nine to fifteen fellows in the program after five years.

University of Tübingen team discovers how malformations of the blood vessels can occur in mice – yielding information with possible ramifications for retinal disease.

Alzheimer's, Parkinson's and other neurodegenerative diseases are associated with inflammatory processes in the brain. German researchers have succeeded in identifying a group of proteins in the liquor that could provide information about such inflammatory processes. As so-called biomarkers, the proteins could help to better understand disease processes in the future and to test the effect of potential drugs against brain inflammation.

Mini-factories for producing bioplastics - 05/05/2022

Bacteria produce bioplastics: resource-saving and very environmentally friendly

Using living cells as mini-factories to produce plastic from nothing more than water, sunlight and carbon dioxide; plastic that is also 100 percent degradable – it sounds far-fetched but it actually works: researchers at the University of Tübingen have genetically engineered cyanobacteria so that they fill their cells to the brim with polyhydroxybutyrate. The researchers are now turning the idea into reality with the development of pilot plants.

Peptide-based COVID-19 vaccine - 21/04/2022

CoVac-1: T-cell activator against COVID-19

Current vaccines against COVID-19 aim at forming neutralising antibodies that prevent the virus from penetrating the host cells. Since people with impaired B-cell immune responses – which can also occur in cancer or autoimmune diseases – are not able to do this, researchers at the University of Tübingen have developed the peptide-based T-cell activator CoVac-1, which promises broad and long-term immunity.

pre-start-up company Wheyfinery - 13/04/2022

Acid whey as a valuable raw material for platform chemicals and more

There is not much you can do with acid whey, which is why several million litres of it are disposed of every year. This is both costly and not sustainable. However, researchers at Tübingen University have shown: acid whey can be used to produce precursors for biofuels, fine chemicals and antimicrobial livestock feed additives. They have set up the pre-start-up company Wheyfinery in an endeavour to make their scalable biorefinery concept…

SolidCAR-T project - 15/03/2022

Modular ‘mini-factories’ for decentralised production of CAR T cells

Novel CAR T-cell therapies have proved to be promising therapeutic options for the treatment of acute leukaemias and lymphomas. Researchers from the Fraunhofer IPA in Stuttgart, the University Hospital Tübingen and the NMI in Reutlingen have joined forces in the SolidCAR-T project that aims to generate CAR T cells to combat solid tumours and produce these cells directly on site in the clinic using automated 'mini-factories'.

Intelligent Diagnostics - 09/02/2022

AI for added value in digital melanoma diagnostics

Intelligent Diagnostics is an interdisciplinary project that brings together the latest technologies and research institutes to better support doctors in diagnosing skin cancer through innovative imaging and artificial intelligence.